Working… Menu

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (GAIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02950051
Recruitment Status : Recruiting
First Posted : October 31, 2016
Last Update Posted : August 1, 2019
Janssen-Cilag Ltd.
Hoffmann-La Roche
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group (NCLLSG)
Swiss Group for Clinical Cancer Research
Cancer Trials Ireland
Israeli CLL Study Group
Information provided by (Responsible Party):
German CLL Study Group

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2024